Basic information Safety Supplier Related

Febuxostat-d9

Basic information Safety Supplier Related

Febuxostat-d9 Basic information

Product Name:
Febuxostat-d9
Synonyms:
  • Febuxostat-d9
  • 2-(3-Cyano-4-isobutyloxyphenyl-d9)-4-Methyl-5-thiazolecarboxylic Acid
  • 2-[3-Cyano-4-(2-Methylpropoxy-d9)phenyl]-4-Methyl-5-thiazolecarboxylic Acid
  • TEI 6720-d9
  • TMX 67-d9
  • [2H9]-Febuxostat
  • Febuxostat-d9 (2-methylpropoxy-d9)
  • Febuxostat D9Q: What is Febuxostat D9 Q: What is the CAS Number of Febuxostat D9 Q: What is the storage condition of Febuxostat D9 Q: What are the applications of Febuxostat D9
CAS:
1246819-50-0
MF:
C16H16N2O3S
MW:
316.37484
Product Categories:
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Heterocycles
  • Isotope Labelled Compounds
  • Pharmaceuticals
Mol File:
1246819-50-0.mol
More
Less

Febuxostat-d9 Chemical Properties

Melting point:
>201°C (dec.)
storage temp. 
Refrigerator
solubility 
Chloroform (Slightly), Methanol (Slightly)
form 
Solid
color 
White to Off-White
More
Less

Febuxostat-d9 Usage And Synthesis

Description

Febuxostat-d9 is intended for use as an internal standard for the quantification of febuxostat by GC- or LC-MS. Febuxostat is an antihyperuricemic nonpurine inhibitor of both the oxidized and reduced forms of xanthine oxidase. It inhibits bovine milk xanthine oxidase as well as mouse and rat liver xanthine oxidase/xanthine dehydrogenase (IC50s = 1.4, 1.8, and 2.2 nM, respectively). It is 10-30 times more potent than the hypoxanthine analog allopurinol (; Kis = 0.7 nM and 0.7 μM, respectively). Febuxostat decreases the serum level of urate in a potassium oxonate rat model of hyperuricemia (ED50 = 1.5 mg/kg). It reduces hepatic macrovesicular steatosis in mice fed a high-fat diet containing trans fatty acids when administered at a dose of 1 mg/kg per day. Febuxostat (0.75 mg/kg) also increases CNS expression of glutamate oxaloacetate transaminase 2 (GOT2) and improves neurological symptoms in a mouse model of secondary progressive experimental autoimmune encephalomyelitis (EAE). Formulations containing febuxostat have been used in the treatment of symptomatic hyperuricemia in patients with gout.

Uses

Febuxostat-d9 is a Labeled compound, intended for use as an internal standard for the quantification of Febuxostat by GC- or LC-mass spectrometry.

Uses

Labelled Febuxostat (F229000). Xanthine oxidase/xanthine dehydrogenase inhibitor. Used for treatment of hyperuricemia and chronic gout.

Febuxostat-d9Supplier

J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
Chemsky (shanghai) International Co.,Ltd
Tel
021-50135380
Email
shchemsky@sina.com
ChemStrong Scientific Co.,Ltd
Tel
0755-0755-66853366 13670046396
Email
sales@chem-strong.com
Artis Biotech Co. Ltd.
Tel
19138486554 18582380095
Email
sales@artisbio.com
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Email
info@efebio.com